Q2 STOCKS TO BUY

OvaScience, Inc. (OVAS) Milestone Rewards Option Bulls

OvaScience Inc's (OVAS) Augment fertility treatment produced its first birth

May 7, 2015 at 2:55 PM
facebook X logo linkedin


OvaScience Inc (NASDAQ:OVAS) traders have been buying to open calls at a breakneck pace recently. The fertility stock's 10-day call/put volume ratio across the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) is 8.13. In other words, more than eight OVAS calls have been bought to open for every put over the last two weeks.

Elsewhere on the Street, 100% of analysts tracking the security rate it a "strong buy." What's more, OVAS' consensus 12-month price target of $64 represents a 148.6% premium to the current price of $25.74-- as well as never-before-charted waters.

Today's strong price action is vindicating these optimists. At last check, OVAS shares were 4.8% higher, after the company's Augment fertility treatment produced its first-ever birth. Longer term, though, the picture isn't so rosy. OvaScience Inc (NASDAQ:OVAS) has plunged 41.5% year-to-date.
 

“Buy This Stock Now!” - Expert Who Called 11x On TSLA

He called a rare 11x on Tesla…

But now, thanks to Elon & Trump’s new alliance…

He says there’s a new opportunity that could be 1,000x BIGGER than Tesla – and it could completely revolutionize a $23 Trillion market.

It’s trading for less than $5 per share right now…

But it won’t be under the radar for long.

Discover The 1,000x Bigger Elon Opportunity Here